Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE.
Michael A TsoukasVincent WooSheldon W TobeApril SleeWally RapattoniFernando G AngJochen SeufertBrendon L NeuenClare ArnottKenneth W MahaffeyDavid C WheelerPublished in: Diabetes, obesity & metabolism (2023)